Avasimibe and atorvastatin synergistically reduce cholesteryl ester content in THP-1 macrophages

European Journal of Pharmacology

Volumn 451, Issue 1, 2002, Pages 11-17

  Llaverías, Gemma ^a   Jové, Mireia ^a   Vázquez Carrera, Manuel ^a   Sánchez, Rosa M ^a   Díaz, Cristina ^b   Hernández, Gonzalo ^b   Laguna, Juan C ^a   Alegret, Marta ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b PFIZER INC   (United States)

Author keywords

Acyl CoA cholesterol acyltransferase; Atorvastatin; Avasimibe; Cholesteryl ester; Hydroxymethyl glutaryl CoA reductase; Macrophage

Indexed keywords

ACETYL LOW DENSITY LIPOPROTEIN; ATORVASTATIN; AVASIMIBE; CHOLESTEROL ACYLTRANSFERASE; CHOLESTEROL ESTER; GERANYLGERANIOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVALONIC ACID;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; MACROPHAGE; PRIORITY JOURNAL;

ACETATES; CELLS, CULTURED; CHOLESTEROL ESTERS; DRUG SYNERGISM; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MACROPHAGES; PYRROLES; SULFONIC ACIDS;

EID: 0037031614     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02152-0     Document Type: Article

References (42)

1. Alegret M., Verd J.C., Diaz C., Hernandez G., Adzet T., Sanchez R.M., Laguna J.C. Effect of hypolipidemic drugs on key enzyme activities related to lipid metabolism in normolipidemic rabbits. Eur. J. Pharmacol. 347:1998;283-291.
2. Auwerx J. The human leukemia cell line, THP-1: a multifaceted model for the study of monocyte-macrophage differentiation. Experientia. 47:1991;22-31.
3. Azuma Y., Kawasaki T., Ikemoto K., Ohno K., Yamada T., Yamasaki M., Nobuhara Y. Effects of NTE-122, a novel acyl-CoA:cholesterol acyltransferase inhibitor, on cholesterol esterification and high-density lipoprotein-induced cholesterol efflux in macrophages. Jpn. J. Pharmacol. 79:1999;159-167.
4. Basu S.K., Goldstein J.L., Anderson G.W., Brown M.S. Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 73:1976;3178-3182.
5. Bernini F., Didoni G., Bonfadini G., Bellosta S., Fumagalli R. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages. Atherosclerosis. 104:1993;19-26.
6. Bernini F., Scurati N., Bonfadini G., Fumagalli R. HMG-CoA reductase inhibitors reduce acetyl LDL endocytosis in mouse peritoneal macrophages. Arterioscler. Thromb. Vasc. Biol. 15:1995;1352-1358.
7. Bocan T.M., Mueller S.B., Uhlendorf P.D., Newton R.S., Krause B.R. Comparison of CI-976, an ACAT inhibitor, and selected lipid-lowering agents for antiatherosclerotic activity in iliac-femoral and thoracic aortic lesions. A biochemical, morphological, and morphometric evaluation. Arterioscler. Thromb. 11:1991;1830-1843.
8. Bocan T.M., Mueller S.B., Uhlendorf P.D., Brown E.Q., Mazur M.J., Black A.E. Inhibition of acyl-CoA cholesterol O-acyltransferase reduces the cholesteryl ester enrichment of atherosclerotic lesions in the Yucatan micropig. Atherosclerosis. 99:1993;175-186.
9. Bocan T.M., Mueller S.B., Brown E.Q., Lee P., Bocan M.J., Rea T., Pape M.E. HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit. Atherosclerosis. 139:1998;21-30.
10. Bocan T.M., Krause B.R., Rosebury W.S., Lu X., Dagle C., Bak Mueller S., Auerbach B., Sliskovic D.R. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis. 157:2001;97-105.
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
12. Buhman K.F., Accad M., Farese R.V. Mammalian acyl-CoA:cholesterol acyltransferases. Biochim. Biophys. Acta. 1529:2000;142-154.
13. Chang T.Y., Chang C.C., Cheng D. Acyl-coenzyme A:cholesterol acyltransferase. Annu. Rev. Biochem. 66:1997;613-638.
14. Cignarella A., Brennhausen B., von Eckardstein A., Assmann G., Cullen P. Differential effects of lovastatin on the trafficking of endogenous and lipoprotein-derived cholesterol in human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1322-1329.
15. Colli S., Eligini S., Lalli M., Camera M., Paoletti R., Tremoli E. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;265-272.
16. Corsini A., Bernini F., Quarato P., Donetti E., Bellosta S., Fumagalli R., Paoletti R., Soma V.M. Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Cardiology. 87:1996;458-468.
17. Davignon J., Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr. Opin. Lipidol. 10:1999;543-559.
18. Doshi R., Wu J., Fishelevich R., Rodriguez A. Update on the role of acyl-CoA:cholesterol acyltransferase inhibitors in atherosclerosis. Expert Opin. Ther. Pat. 11:2001;1655-1662.
19. Guardiola F., Codony R., Rafecas M., Boatella J. Selective gas chromatographic determination of cholesterol in eggs. J. Am. Oil Chem. Soc. 71:1994;867-871.
20. Hakamata H., Miyazaki A., Sakai M., Sakamoto Y.I., Matsuda H., Kihara K., Horiuchi S. Differential effects of an acyl-coenzyme A:cholesterol acyltransferase inhibitor on HDL-induced cholesterol efflux from rat macrophage foam cells. FEBS Lett. 363:1995;29-32.
21. Insull W. Jr., Koren M., Davignon J., Sprecher D., Schrott H., Keilson L.M., Brown A.S., Dujovne C.A., Davidson M.H., McLain R., Heinonen T. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis. 157:2001;137-144.
22. Ishii I., Yokoyama N., Yanagimachi M., Ashikawa N., Hata M., Murakami S., Asami Y., Morisaki N., Saito Y., Ohmori S., Kitada M. Stimulation of cholesterol release from rabbit foam cells by the action of a new inhibitor for acylCoA:cholesterol acyltransferase (ACAT), HL-004. J. Pharmacol. Exp. Ther. 287:1998;115-121.
23. Junquero D., Bruniquel F., N'Guyen X., Autin J.M., Patoiseau J.F., Degryse A.D., Colpaert F.C., Delhon A. F 12511, a novel ACAT inhibitor, and atorvastatin regulate endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. Atherosclerosis. 155:2001;131-142.
24. Kellner-Weibel G., Jerome W.G., Small D.M., Warner G.J., Stoltenborg J.K., Kearney M.A., Corjay M.H., Phillips M.C., Rothblat G.H. Effects of intracellular free cholesterol accumulation on macrophage viability: a model for foam cell death. Arterioscler. Thromb. Vasc. Biol. 18:1998;423-431.
25. Kellner-Weibel G., Geng Y.J., Rothblat G.H. Cytotoxic cholesterol is generated by the hydrolysis of cytoplasmatic cholesteryl ester and transported to the plasma membrane. Atherosclerosis. 146:1999;309-319.
26. Klansek J.J., Yancey P., St. Clair R.W., Fischer R.T., Johnson W.J., Glick J.M. Cholesterol quantitation by GLC: artifactual formation of short-chain steryl esters. J. Lipid Res. 36:1995;2261-2266.
27. Kusunoki J., Hansoty D.K., Aragane K., Fallon J.T., Badimon J.J., Fisher E.A. Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103:2001;2604-2609.
28. Lee H.T., Sliskovic D.R., Picard J.A., Roth B.D., Wierenga W., Hicks J.L., Bousley R.F., Hamelehle K.L., Homan R., Speyer C., Stanfield R.L., Krause B.R. Inhibitors of acyl-CoA: cholesterol O-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J. Med. Chem. 39:1996;5031-5034.
29. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
30. McCrohon J.A., Nakhla S., Jessup W., Stanley K.K., Celermajer D.S. Estrogen and progesterone reduce lipid accumulation in human monocyte-derived macrophages: a sex-specific effect. Circulation. 100:1999;2319-2325.
31. Mills G.L., Lane P.A., Weech P.K. The isolation and purification of plasma lipoproteins. Mills G.L., Lane P.A., Weech P.K. A Guidebook to Lipoprotein Technique. 1984;25-50 Elsevier, Amsterdam.
32. Miyazaki A., Sakashita N., Lee O., Takahashi K., Horiuchi S., Hakamata H., Morganelli P.M., Chang C.C., Chang T.Y. Expression of ACAT1 protein in human atherosclerotic lesions and cultured human monocytes-macrophages. Arterioscler. Thromb. Vasc. Biol. 18:1998;1568-1574.
33. Mossman T. Rapid colorimetric assay for cell growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65:1983;55-63.
34. Ohgami N., Kuniyasu A., Furukawa K., Miyazaki A., Hakamata H., Horiuchi S., Nakayama H. Glibenclamide acts as an inhibitor of acyl-CoA:cholesterol acyltransferase enzyme. Biochem. Biophys. Res. Commun. 277:2000;417-422.
35. Perrey S., Legendre C., Matsuura A., Guffroy C., Binet J., Ohbayashi S., Tanaka T., Ortuno J.C., Matsukura T., Laugel T., Padovani P., Bellamy F., Edgar A.D. Preferential pharmacological inhibition of macrophage ACAT increases plaque formation in mouse and rabbit models of atherogenesis. Atherosclerosis. 155:2001;359-370.
36. Ravandi A., Kuksis A., Shaikh N.A. Glycated phosphatidylethanolamine promotes macrophage uptake of low density lipoprotein and accumulation of cholesteryl esters and triacylglycerols. J. Biol. Chem. 274:1999;16494-16500.
37. Rodriguez A., Bachorik P.S., Wee S.B. Novel effects of the acyl-coenzyme A:cholesterol acyltransferase inhibitor 58-035 on foam cell development in primary human monocyte-derived macrophages. Arterioscler. Thromb. Vasc. Biol. 19:1999;2199-2206.
38. Ross R. The pathogenesis of atherosclerosis: an update. New Engl. J. Med. 314:1986;488-500.
39. Roth B.D. ACAT-inhibitors: evolution from cholesterol-absorption inhibitors to antiatherosclerotic agents. Drug Discov. Today. 3:1998;19-25.
40. Sliskovic D.R., White A.D. Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents. Trends Pharmacol. Sci. 12:1991;194-199.
41. Verd J.C., Peris C., Alegret M., Diaz C., Hernandez G., Vazquez M., Adzet T., Laguna J.C., Sanchez R.M. Different effect of simvastatin and atorvastatin on key enzymes involved in VLDL synthesis and catabolism in high fat/cholesterol fed rabbits. Br. J. Pharmacol. 127:1999;1479-1485.
42. Warner G.J., Stoudt G., Bamberger M., Johnson W.J., Rothblat G.H. Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol. J. Biol. Chem. 270:1995;5772-5778.